search
Back to results

Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants

Primary Purpose

Malaria, Anemia

Status
Completed
Phase
Phase 4
Locations
Ghana
Study Type
Interventional
Intervention
Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)
Sponsored by
Bernhard Nocht Institute for Tropical Medicine
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Malaria focused on measuring Malaria, Anemia, IPTi, Intermittent Preventive Treatment in Infants, Sulfadoxine-Pyrimethamine, Chemoprophylaxis, Ghana

Eligibility Criteria

2 Months - 4 Months (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Informed consent by parent/guardian (written or oral) Permanent residentship in the study area Age of 3 months +/-4 weeks Exclusion Criteria: Hypersensitivity to sulfonamides or pyrimethamine (skin rashes, evidence of hemolysis including dark urine and/or purpura, presumptive signs of bone marrow depression such as sore throat and/or mouth ulcers) Other severe adverse events related to pyrimethamine-sulfadoxine application Signs of severe hepatic or renal dysfunction not due to malaria Other reasons after decision of the study physician

Sites / Locations

  • Kumasi Centre for Collaborative Research in Tropical Medicine

Outcomes

Primary Outcome Measures

• Efficacy of an extended intermittent treatment with sulfadoxine-pyrimethamine for the control of clinical malaria and anemia (proportion and rates of children with one or more episodes of malaria or anemia in the age of 3 to 21 months of life)
• Determination of the rate of clinical malaria and anemia after suspending an extended intermittent treatment for analysis of possible rebound effects
• Evaluation of safety and adverse effects of the administration of single doses of sulfadoxine-pyrimethamine in infants and children

Secondary Outcome Measures

• Rate and time points of hospitalizations with anemia, malaria or other diseases
• Rate and time points of severe anemia episodes
• Proportion and rates of children with one or more episodes of malaria or anemia in the age of 3 to 12 months of life
• Antibody responses against parasite antigens
• Multiplicity of P. falciparum infections
• Proportion of P. falciparum isolates with SP resistance
• Influence of host genetic variants on the rate of P. falciparum infections

Full Information

First Posted
September 13, 2005
Last Updated
March 29, 2010
Sponsor
Bernhard Nocht Institute for Tropical Medicine
Collaborators
German Federal Ministry of Education and Research, Deutscher Akademischer Austausch Dienst, The Volkswagen Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00206739
Brief Title
Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants
Official Title
Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infant: a Randomized, Double-blind, and Placebo-controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2005
Overall Recruitment Status
Completed
Study Start Date
January 2003 (undefined)
Primary Completion Date
September 2005 (Actual)
Study Completion Date
September 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Bernhard Nocht Institute for Tropical Medicine
Collaborators
German Federal Ministry of Education and Research, Deutscher Akademischer Austausch Dienst, The Volkswagen Foundation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess the effectiveness of Intermittent Preventive Treatment in Infants (IPTi) with Sulfadoxine-Pyrimethamine to reduce the numbers of malaria attacks, episodes of anemia, and the overall morbidity and mortality
Detailed Description
In order to define the effectiveness of Intermittent Preventive Treatment in Infants (IPTi) with Sulfadoxine-Pyrimethamine, a novel principle of malaria intervention, the following parameters are evaluated: i) the level of protection from malaria attacks and episodes of anemia during the treatment period, ii) the level of protection from severe malaria during the treatment period, iii) the effect on malaria morbidity after sustaining treatment, iv) the decrease of overall morbidity and mortality, including the number of hospital admissions and visits of hospital outpatient departments v) the influence of the intervention on the development of drug resistances, vi) the impact of the intervention on the development of immunity, vii) the possible influence of the intervention on sub-clinical organ dysfunction due to chronic Plasmodium falciparum infection. Parts of the study are performed in collaboration with the Laboratory of Research, Hospital Albert Schweitzer, Lambaréné, Gabon and the School of Medicine and Health Sciences, University of Development Studies, Tamale, Ghana

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria, Anemia
Keywords
Malaria, Anemia, IPTi, Intermittent Preventive Treatment in Infants, Sulfadoxine-Pyrimethamine, Chemoprophylaxis, Ghana

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1070 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)
Primary Outcome Measure Information:
Title
• Efficacy of an extended intermittent treatment with sulfadoxine-pyrimethamine for the control of clinical malaria and anemia (proportion and rates of children with one or more episodes of malaria or anemia in the age of 3 to 21 months of life)
Title
• Determination of the rate of clinical malaria and anemia after suspending an extended intermittent treatment for analysis of possible rebound effects
Title
• Evaluation of safety and adverse effects of the administration of single doses of sulfadoxine-pyrimethamine in infants and children
Secondary Outcome Measure Information:
Title
• Rate and time points of hospitalizations with anemia, malaria or other diseases
Title
• Rate and time points of severe anemia episodes
Title
• Proportion and rates of children with one or more episodes of malaria or anemia in the age of 3 to 12 months of life
Title
• Antibody responses against parasite antigens
Title
• Multiplicity of P. falciparum infections
Title
• Proportion of P. falciparum isolates with SP resistance
Title
• Influence of host genetic variants on the rate of P. falciparum infections

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Months
Maximum Age & Unit of Time
4 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Informed consent by parent/guardian (written or oral) Permanent residentship in the study area Age of 3 months +/-4 weeks Exclusion Criteria: Hypersensitivity to sulfonamides or pyrimethamine (skin rashes, evidence of hemolysis including dark urine and/or purpura, presumptive signs of bone marrow depression such as sore throat and/or mouth ulcers) Other severe adverse events related to pyrimethamine-sulfadoxine application Signs of severe hepatic or renal dysfunction not due to malaria Other reasons after decision of the study physician
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ohene Adjei, Prof. Dr.
Organizational Affiliation
Kumasi Centre for Collaborative Research in Tropical Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jürgen May, PD Dr.
Organizational Affiliation
Bernhard Nocht Institute for Tropical Medicine Hamburg, Infection Epidemiology
Official's Role
Study Director
Facility Information:
Facility Name
Kumasi Centre for Collaborative Research in Tropical Medicine
City
Kumasi
State/Province
Ashanti Region
Country
Ghana

12. IPD Sharing Statement

Citations:
PubMed Identifier
11377597
Citation
Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, Mshinda H, Alonso P. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 2001 May 12;357(9267):1471-7. doi: 10.1016/S0140-6736(00)04643-2.
Results Reference
background
PubMed Identifier
9310602
Citation
Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, Acosta CJ, Schellenberg DM, Galindo CM, Kimario J, Urassa H, Brabin B, Smith TA, Kitua AY, Tanner M, Alonso PL. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. Lancet. 1997 Sep 20;350(9081):844-50. doi: 10.1016/S0140-6736(97)04229-3.
Results Reference
background
PubMed Identifier
12788572
Citation
Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, Ronn AM, Theander TG, Bygbjerg IC. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. Lancet. 2003 May 31;361(9372):1853-60. doi: 10.1016/s0140-6736(03)13504-0.
Results Reference
background
PubMed Identifier
12354473
Citation
Verhoef H, West CE, Nzyuko SM, de Vogel S, van der Valk R, Wanga MA, Kuijsten A, Veenemans J, Kok FJ. Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial. Lancet. 2002 Sep 21;360(9337):908-14. doi: 10.1016/S0140-6736(02)11027-0. Erratum In: Lancet 2002 Oct 19;360(9341):1256.
Results Reference
background
PubMed Identifier
18828899
Citation
May J, Adjei S, Busch W, Gabor JJ, Issifou S, Kobbe R, Kreuels B, Lell B, Schwarz NG, Adjei O, Kremsner PG, Grobusch MP. Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon. Malar J. 2008 Oct 1;7:198. doi: 10.1186/1475-2875-7-198.
Results Reference
derived
PubMed Identifier
18067679
Citation
Kobbe R, Adjei S, Kreuzberg C, Kreuels B, Thompson B, Thompson PA, Marks F, Busch W, Tosun M, Schreiber N, Opoku E, Adjei O, Meyer CG, May J. Malaria incidence and efficacy of intermittent preventive treatment in infants (IPTi). Malar J. 2007 Dec 9;6:163. doi: 10.1186/1475-2875-6-163.
Results Reference
derived
Links:
URL
http://www.kccr.de/kccr/
Description
Homepage of the Kumasi Centre for Collaborative Research (study site)

Learn more about this trial

Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants

We'll reach out to this number within 24 hrs